Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVASE trial: nebulised dornase alfa to reduce hyperinflammation in hospitalised COVID-19 patients
2020-001937-11Phase 2Unknown
- Sponsor
- University College London
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Dornase alfa (Pulmozyme) nebulised plus standard of care with Standard of care alone (control) (2 arms). Primary endpoint: Change from baseline in C-reactive protein (CRP). Status: unknown.
02
Drugs
dornase alfa
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001937-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001937-11.